

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



June 06, 2024

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition

This is to inform that Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as “Sun Pharma”), has entered into an agreement with HaystackAnalytics Private Limited (“Haystack”), pursuant to which Sun Pharma has agreed to acquire 9.6 % of total outstanding securities.

The particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III are provided in **Annexure A**, enclosed herewith.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>HaystackAnalytics Private Limited (“Haystack”), a company registered under the Companies Act, 2013, having the corporate identification number (‘CIN’) U72900MH2018PTC313413 and having its registered office at CM 03, Society for Innovation & Entrepreneurship (SINE), 4th Floor, KReSIT Building, IIT Bombay, Powai, Mumbai -400076.</p> <p>HaystackAnalytics is engaged in the business of developing genomic analysis software that enables clinical decision-making through culture-free, comprehensive, and fast clinical genomics by automating bioinformatic analysis to produce clear and clinically relevant reports and utilization of the genomic data and their analysis for creation of new products for healthcare.</p> <p>The revenue from operations for FY2023 is Rs 3.13 Crore.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.
c)	Industry to which the entity being acquired belongs	Healthcare
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if	Non-material investment in allied areas.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



	its business is outside the main line of business of the listed entity)									
e)	Brief details of any governmental or regulatory approvals required for the acquisition	None								
f)	Indicative time period for completion of the acquisition	By July 2024 subject to satisfactory completion of certain conditions.								
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash								
h)	Cost of acquisition or the price at which the shares are acquired	Rs. 33.00 Crore								
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	9.61% of total outstanding securities								
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Haystack is engaged in the business of developing genomic analysis software that enables clinical decision-making through culture-free, comprehensive, and fast clinical genomics by automating bioinformatic analysis to produce clear and clinically relevant reports and utilization of the genomic data and their analysis for creation of new products for healthcare</p> <p>Haystack was incorporated on September 4, 2018.</p> <p>The revenue from operations for previous three years is as follows,</p> <table border="1"> <thead> <tr> <th>FY</th> <th>Turnover (in INR)</th> </tr> </thead> <tbody> <tr> <td>2022-23</td> <td>3,12,84,614</td> </tr> <tr> <td>2021-22</td> <td>2,00,62,570</td> </tr> <tr> <td>2020-21</td> <td>51,000</td> </tr> </tbody> </table>	FY	Turnover (in INR)	2022-23	3,12,84,614	2021-22	2,00,62,570	2020-21	51,000
FY	Turnover (in INR)									
2022-23	3,12,84,614									
2021-22	2,00,62,570									
2020-21	51,000									

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.